Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018;62(1):385-397.
doi: 10.3233/JAD-170602.

Cerebrospinal Fluid and Plasma Levels of Inflammation Differentially Relate to CNS Markers of Alzheimer's Disease Pathology and Neuronal Damage

Brianne M Bettcher  1 , Sterling C Johnson  2   3 , Ryan Fitch  4 , Kaitlin B Casaletto  4 , Kate S Heffernan  1 , Sanjay Asthana  2   3 , Henrik Zetterberg  5   6   7 , Kaj Blennow  5   6 , Cynthia M Carlsson  2   3 , John Neuhaus  8 , Barbara B Bendlin  2 , Joel H Kramer  4
Affiliations

Cerebrospinal Fluid and Plasma Levels of Inflammation Differentially Relate to CNS Markers of Alzheimer's Disease Pathology and Neuronal Damage

Brianne M Bettcher et al. J Alzheimers Dis. 2018.

Abstract

Inflammatory markers have been shown to predict neurocognitive outcomes in aging adults; however, the degree to which peripheral markers mirror the central nervous system remains unknown. We investigated the association between plasma and cerebrospinal fluid (CSF) markers of inflammation, and explored whether these markers independently predict CSF indicators of Alzheimer's disease (AD) pathology or neuronal damage. Plasma and CSF samples were analyzed for inflammatory markers in a cohort of asymptomatic older adults (n = 173). CSF samples were analyzed for markers of AD pathology (Aβ42, phosphorylated tau [p-tau], sAβPPβ) or neuronal damage (total tau; neurofilament light chain) (n = 147). Separate linear models for each analyte were conducted with CSF and plasma levels entered simultaneously as predictors and markers of AD pathology or neuronal damage as outcome measures. Strong associations were noted between CSF and plasma MIP-1β levels, and modest associations were observed for remaining analytes. With respect to AD pathology, higher levels of plasma and CSF IL-8, CSF MIP-1β, and CSF IP-10 were associated with higher levels of p-tau. Higher levels of CSF IL-8 were associated with higher levels of CSF Aβ42. Higher CSF sAβPPβ levels were associated with higher plasma markers only (IL-8; MCP-1). In terms of neuronal injury, higher levels of plasma and CSF IL-8, CSF IP-10, and CSF MIP-1β were associated with higher levels of CSF total tau. Exploratory analyses indicated that CSF Aβ42 modifies the relationship between plasma inflammatory levels and CSF tau levels. Results suggest that both plasma and CSF inflammatory markers independently relay integral information about AD pathology and neuronal damage.

Keywords: Aging; Alzheimer’s disease; biomarkers; neuroinflammation; preclinical AD; systemic inflammation.

PubMed Disclaimer

Conflict of interest statement

The authors have no other disclosures or conflicts of interest.

Figures

Figure 1
Figure 1
Displays pearson correlations between plasma and CSF for each inflammatory marker. Bands represent a 95% confidence interval based on Fisher’s transformation.
Figure 2
Figure 2
Displays the pearson correlations between inflammatory markers and age as a function of specimen type (plasma; CSF); bars represent 95% confidence intervals based on Fisher’s transformation.
Figure 3
Figure 3
Figure displays the association between inflammatory markers and p-tau levels as a function of CSF Aβ42 quartiles. P-tau levels were adjusted for demographics and APOE status. Significant interactions were observed for both plasma MCP-1 and plasma IP-10, such that stronger positive correlations between inflammatory markers and CSF p-tau were observed when CSF Aβ42 levels
See this image and copyright information in PMC

References

    1. Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci. 2015;16:358–372. - PubMed
    1. Blasko I, Stampfer-Kountchev M, Robatscher P, Veerhuis R, Eikelenboom P, Grubeck-Loebenstein B. How chronic inflammation can affect the brain and support the development of Alzheimer’s disease in old age: the role of microglia and astrocytes. Aging Cell. 2004;3:169–176. - PubMed
    1. Eikelenboom P, Hoozemans JJ, Veerhuis R, van Exel E, Rozemuller AJ, van Gool WA. Whether, when and how chronic inflammation increases the risk of developing late-onset Alzheimer’s disease. Alzheimers Res Ther. 2012;4:15. - PMC - PubMed
    1. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med. 2006;12:1005–1015. - PubMed
    1. Galimberti D, Fenoglio C, Scarpini E. Inflammation in neurodegenerative disorders: friend or foe? Curr Aging Sci. 2008;1:30–41. - PubMed

Publication types